Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Net Cash Flow: 2013-2024

Historic Net Cash Flow for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$121.9 million.

  • ImmunityBio's Net Cash Flow fell 322.84% to -$76.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year increase of 22.66%. This contributed to the annual value of -$121.9 million for FY2024, which is 175.63% down from last year.
  • Latest data reveals that ImmunityBio reported Net Cash Flow of -$121.9 million as of FY2024, which was down 175.63% from $161.1 million recorded in FY2023.
  • ImmunityBio's 5-year Net Cash Flow high stood at $161.1 million for FY2023, and its period low was -$121.9 million during FY2024.
  • For the 3-year period, ImmunityBio's Net Cash Flow averaged around -$12.4 million, with its median value being -$76.6 million (2022).
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 457.65% in 2021, then plummeted by 175.63% in 2024.
  • Over the past 5 years, ImmunityBio's Net Cash Flow (Yearly) stood at -$40.9 million in 2020, then spiked by 457.65% to $146.1 million in 2021, then crashed by 152.42% to -$76.6 million in 2022, then soared by 310.33% to $161.1 million in 2023, then crashed by 175.63% to -$121.9 million in 2024.